Survodutide Dosage: The Phase 3 Trial Schedule
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ⚠️ Investigational — trial data only
← Survodutide encyclopedia entry · See also: Retatrutide dosage · CagriSema dosage
Survodutide is an investigational drug in Phase 3 trials; it is not approved by the FDA or any regulator. The doses below come only from clinical trials and are administered under medical supervision within those studies. This page is educational — it is not a protocol, and survodutide is not available as an approved medicine.
The short version
Survodutide (development code BI 456906, from Boehringer Ingelheim and Zealand Pharma) is a GLP-1/glucagon dual receptor agonist. It belongs to the same wave of next-generation metabolic drugs as retatrutide, but with a distinct receptor combination — adding glucagon-receptor activity to GLP-1, which is of particular interest for reducing liver fat. Because it is still in trials, the only meaningful "dose" is the trial dose, and that exists inside a supervised research setting.
The trial dosing approach
Across its development, survodutide has been given once weekly by subcutaneous injection, with a stepwise titration upward to limit the nausea and other gastrointestinal effects common to incretin therapies. The Phase 2 program used target doses in the low-single-digit milligram range and demonstrated roughly 19% weight loss, which placed it among the higher-efficacy investigational agents; the Phase 3 SYNCHRONIZE (obesity) and LIVERAGE (MASH) programs are evaluating it further.
| Parameter | As used in trials |
|---|---|
| Route | Subcutaneous |
| Frequency | Once weekly |
| Titration | Stepwise up-titration |
| Status | Phase 3 (not approved) |
The titration logic is the same as the approved GLP-1 drugs: start low, step up, let the gut adapt. The difference is that survodutide's schedule has not been finalized into an approved label, so any specific milligram targets are trial parameters, not prescribing instructions.
Regulatory status
Survodutide received FDA Breakthrough Therapy designation for MASH (non-cirrhotic, with moderate-to-advanced fibrosis) in 2024 — a designation that expedites development and review but is not an approval. As of this writing it remains investigational with Phase 3 readouts pending. "Research" survodutide sold outside of trials is not the trial drug and is not quality-assured. See the Regulatory Status Tracker and our retatrutide dosage page for how investigational incretins are framed here.
Frequently asked questions
When might survodutide be approved?
That depends on the Phase 3 readouts and subsequent regulatory filings, which had not produced an approval at the time of writing. Timelines for investigational drugs are uncertain.
Is the glucagon component risky?
Glucagon-receptor agonism is the feature that distinguishes it, and its safety and metabolic effects are precisely what the trials are characterizing — which is why use outside a trial is not advisable.
How does it compare to retatrutide?
Retatrutide is a triple agonist (GLP-1/GIP/glucagon); survodutide is dual (GLP-1/glucagon). Both are investigational. See the retatrutide hub.
Sources
- Boehringer Ingelheim / Zealand Pharma — survodutide (BI 456906) Phase 3 SYNCHRONIZE and LIVERAGE program; FDA Breakthrough Therapy designation for MASH (2024).
- Le Roux CW, et al. Survodutide Phase 2 obesity trial results.
Medical disclaimer: Education only, not medical advice. Survodutide is investigational and not approved for any use. Trial doses apply only within supervised studies. Consult a licensed clinician.